Inventor · disambiguated record
Thomas Hofer
Also filed as: HOFER THOMAS · HOFER THOMAS U
30 granted patents·37 pending applications·542 citations·filing 2009–2024
97Inventor score
Top patents by PatentIndex Score
67 records- 0198US11130822B2ImmunoconjugatesROCHE GLYCART AG·Filed 2019·Granted Sep 28, 2021·16 cites·24 claims
- 0298US10316104B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Jun 11, 2019·30 cites·23 claims
- 0398US10202464B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Feb 12, 2019·30 cites·3 claims
- 0498US10184009B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2017·Granted Jan 22, 2019·37 cites·30 claims
- 0598US9447159B2ImmunoconjugatesAST OLIVER·Filed 2012·Granted Sep 20, 2016·111 cites·27 claims
- 0697US10323098B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2016·Granted Jun 18, 2019·25 cites·30 claims
- 0797US9266938B2Mutant interleukin-2 polypeptidesAST OLIVER·Filed 2012·Granted Feb 23, 2016·123 cites·25 claims
- 0896US11111312B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2018·Granted Sep 7, 2021·8 cites·5 claims
- 0996US9206260B2Anti-CEA antibodiesROCHE GLYCART AG·Filed 2013·Granted Dec 8, 2015·23 cites·13 claims
- 1095US8642742B2Anti-CEA antibodiesHOFER THOMAS U·Filed 2012·Granted Feb 4, 2014·38 cites·18 claims
- 1194US9068008B2Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereofMÖSSNER EKKEHARD·Filed 2010·Granted Jun 30, 2015·33 cites·25 claims
- 1293US11591397B2Bispecific antibody molecules binding to CD3 and EGFRvIIIHOFFMANN LA ROCHE·Filed 2021·Granted Feb 28, 2023·2 cites·15 claims
- 1393US10781258B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·4 cites·39 claims
- 1493US10155815B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2014·Granted Dec 18, 2018·12 cites·46 claims
- 1592US11608376B2Tumor-targeted agonistic CD28 antigen binding moleculesHOFFMANN LA ROCHE·Filed 2019·Granted Mar 21, 2023·14 cites·49 claims
- 1692US9771427B2ASGPR antibodies and uses thereofROCHE GLYCART AG·Filed 2013·Granted Sep 26, 2017·16 cites·25 claims
- 1788US8916159B2Selenocysteine mediated hybrid antibody moleculesRADER CHRISTOPH·Filed 2009·Granted Dec 23, 2014·13 cites·22 claims
- 1886US11672858B2Bispecific antibody molecules binding to CD3 and TYRP-1HOFFMANN LA ROCHE·Filed 2019·Granted Jun 13, 2023·2 cites·16 claims
- 1986US2023365711A1Anti-cea antibodiesROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 2085US10781257B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·1 cites·34 claims
- 2184US12473373B2Bispecific antibody molecules binding to CD3 and EGFRvIIIHOFFMANN LA ROCHE·Filed 2023·Granted Nov 18, 2025·0 cites·30 claims
- 2283US12049515B2Agonistic CD28 antigen binding molecules targeting Her2HOFFMANN LA ROCHE·Filed 2021·Granted Jul 30, 2024·1 cites·37 claims
- 2383US2023076791A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2022·Application pending·0 cites
- 2481US12129306B2Antibodies binding to STEAP-1HOFFMANN LA ROCHE·Filed 2023·Granted Oct 29, 2024·0 cites·1 claims
- 2581US11180571B2Antibodies binding to STEAP-1HOFFMANN LA ROCHE·Filed 2019·Granted Nov 23, 2021·1 cites·31 claims
- 2681US2022064296A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 2780US2023277662A1Antibodies binding to cd3HOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2879US2022242971A1Novel immunoconjugatesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 2979US2022002441A1Anti-cea antibodiesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 3078US10584178B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 10, 2020·2 cites·6 claims
- 3178US2021253703A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 3278US2021253704A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 3377US2021101979A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 3475US11685790B2Antibodies binding to STEAP-1HOFFMANN LA ROCHE·Filed 2021·Granted Jun 27, 2023·0 cites·1 claims
- 3575US2020385470A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 3672US10975151B2ASPGR antibodies and uses thereofROCHE GLYCART AG·Filed 2019·Granted Apr 13, 2021·0 cites·18 claims
- 3772US2021324085A1Aspgr antibodies and uses thereofROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 3871US2025059298A1Agonistic cd28 antigen binding molecules targeting her2HOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 3970US2019177413A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2019·Application pending·0 cites
- 4069US2019185583A1Anti-cea antibodiesROCHE GLYCART AG·Filed 2019·Application pending·0 cites
- 4169US2018312589A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 4267US2019322763A1Novel immunoconjugatesROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 4366US2019322765A1Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2019·Application pending·0 cites
- 4465US2024368309A1Agonistic cd28 antigen binding molecules targeting epcamHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 4564US12466889B2Anti-HLA-G antibodies and use thereofHOFFMANN LA ROCHE·Filed 2022·Granted Nov 11, 2025·0 cites·91 claims
- 4664US2018079827A1Anti-cea antibodiesROCHE GLYCART AG·Filed 2017·Application pending·0 cites
- 4763US11787873B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·0 cites·17 claims
- 4862US10087254B2ASPGR antibodies and uses thereofROCHE GLYCART AG·Filed 2017·Granted Oct 2, 2018·0 cites·5 claims
- 4962US2019031760A1Aspgr antibodies and uses thereofROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 5062US2023416366A1Anti-cd3/anti-cd28 bispecific antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thomas Hofer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →